This report has covered many areas of the management of type 1 diabetes; however, the writing group recognizes that huge gaps exist in our knowledge in the prevention, diagnosis, and treatment of the disease. People with type 1 diabetes deserve better, higher quality research evidence on which to determine their optimal care (Diabetes Care)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria (Diabetes Care)
Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening
We have identified subtle (nonpathological) changes in neonatal metabolism that represent a signature effect of fetal metformin exposure (Diabetes Care)
Adult-Onset Type 1 Diabetes: Current Understanding and Challenges
By providing this perspective, we aim to improve the management of adults presenting with type 1 diabetes (DiabetesCare)
Dissociation of Glycated Albumin and HbA1c Is Associated With a Decline of Glomerular Filtration Rate as Evaluated by Inulin Clearance
In conclusion, GA and HbA1c are dissociated by GFR reduction in patients with glycemic disorder, and eGFR and HbA1c may not provide an accurate measure of the risk of DKD. Thus, care is needed in evaluating glycemic control using HbA1c in patients with kidney dysfunction (Diabetes Care)
Incidence Rates and Predictors of Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes: Results from the Longitudinal Global DISCOVER Study
In this global study, both the prevalence and 3-year incidence of vascular complications were high in patients with relatively short T2D duration, highlighting the need for early risk-factor modification (American Heart Journal)
Optimal glucose, HbA1c, glucose-HbA1c ratio and stress-hyperglycaemia ratio cut-off values for predicting 1-year mortality in diabetic and non-diabetic acute myocardial infarction patients
SHR was the most consistent independent predictor of 1-year all-cause mortality in both diabetic and non-diabetic STEMI, whereas glucose was the best predictor in NSTEMI patients (Cardiovascular Diabetology)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
In people with type 2 diabetes and elevated cardiovascular risk, tirzepatide, compared with glargine, demonstrated greater and clinically meaningful HbA1c reduction with a lower incidence of hypoglycaemia at week 52. Tirzepatide treatment was not associated with excess cardiovascular risk (Lancet)
Forxiga
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Forxiga (EMA)
Exploring the determinants of ethnic differences in insulin clearance between men of Black African and White European ethnicity
These data suggest that adiponectin may play a direct role in the upregulation of insulin clearance beyond its insulin-sensitising properties (Acta Diabetologica)
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial
Our study showed that gemigliptin significantly improved the expression of renal tubular injury biomarkers and vascular calcification levels among patients with DKD; however, gemigliptin did not affect renal function or coronary calcification compared with those observed in the control (Journal of Diabetes Research)
Diet-induced fasting ghrelin elevation reflects the recovery of insulin sensitivity and visceral adiposity regression
Diet-induced FGL elevation may reflect insulin sensitivity recovery and VAT regression beyond weight-loss, specifically among men. Green-MED diet is associated with greater FGL elevation (Journal of Clinical Endocrinology & Metabolism)
Empagliflozin Treatment is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
Empagliflozin thus ameliorates the ‘cardiac energy-deficient’ state, regresses adverse myocardial cellular remodelling, and improves cardiac function, offering therapeutic opportunities to prevent or modulate heart failure in T2D (Diabetes)
GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
Overall, the results of CVOTs published so far seems to suggest that the gap between the cardiorenal benefits of SGLT-2 and GLP-1RA is narrowing (Cardiovascular Diabetology)
Low glycaemic state increases risk of frailty and functional decline in older people with type 2 diabetes mellitus – evidence from a systematic review
Low glycaemia increases risk of frailty and functional decline in older people with type 2 diabetes. Management should minimise incidence of low glycaemia in these patients (Diabetes Research and Clinical Practice)
Estimated glucose disposal rate and risk of stroke and mortality in type 2 diabetes: a nationwide cohort study
A low eGDR (a measure of insulin resistance) is associated with an increased risk of stroke and death in individuals with T2D. The relative attributed risk was most important for hypertension (Cardiovascular Diabetology)
Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort
In this study, a high HbA1c did not reduce the occurrence of nocturnal hypoglycemia, and low HbA1c was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters (Diabetes Care)
Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study
This study supports the renoprotective benefit of real-world SGLT-2i use irrespective of patient baseline kidney function (Cardiovascular Diabetology)
Effects of SGLT-2 inhibitors on serum uric acid in patients with T2DM: A systematic review and network meta-analysis
SGLT-2 inhibitors could significantly reduce SUA levels in patients with T2DM, especially luseogliflozin (1 mg and 10 mg) and dapagliflozin (5 mg) possess the best effects. Therefore, SGLT-2 inhibitors look extremely promising as an anti-diabetes treatment option in patients with T2DM with high SUA (Diabetes, Obesity and Metabolism)
COncise adVice on Inpatient Diabetes (COVID:Diabetes)
Post COVID-19 diebetes discharge pathway – risk stratification and follow up guidance for people being discharged from secondary care after COVID-19 infection (ABCD)
- 1
- 2
- 3
- …
- 225
- Next Page »
Glycosmedia is also available as an App: